The words and actions of US President Donald Trump are rocking the pharmaceutical industry. On May 5, he said he…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Kaken President Onuma Targets ¥20 Billion in Operating Profits in 2015
September 21, 2011
-
ORGANIZATION FPMAJ Seeks Improved System for Orphan Drug Development, Request to Be Submitted Soon to Health Minister
September 20, 2011
-
REGULATORY HSC Subcommittee Agrees on Need for New System to Promote Access to Unapproved Drugs
September 20, 2011
-
REGULATORY Preparations Underway for MHLW to Set Up Private Third-Party Committee
September 16, 2011
-
REGULATORY Council Recommends 5 Drugs as Appropriate for Application Based on Info. in Public Domain
September 16, 2011
-
BUSINESS Small, Medium-Sized Generic Drug Makers’ Business Improves Amid Uncertainty Over Future
September 15, 2011
-
BUSINESS Supreme Court Rules Against GE Drug Makers, Allows Patent Extension for Eisai’s Aricept
September 15, 2011
-
ACADEMIA NCGM Hospital Removes Actos from List of Recommended Drugs in Diabetes Manual
September 14, 2011
-
ORGANIZATION FPMAJ Announces Its Basic Policy on Providing Info. on Drugs Used Off-label
September 13, 2011
-
BUSINESS Takeda Initiates PIII Trials of Antidiabetic TAK-875 in Japan
September 13, 2011
-
BUSINESS NBI Initiates PIII Study for BIBF1122 in Japan
September 12, 2011
-
REGULATORY MHLW Director-General Kikura Indicates “Firm Resolve” for Structural Improvement to Eliminate Drug Disasters
September 12, 2011
-
ACADEMIA Clinical Positioning Needs to Be Clarified for Nexavar, Sutent: Prof. Naito of Kyushu Univ.
September 12, 2011
-
REGULATORY MHLW’s Council to Draw Up 10-Year Strategy for Hepatitis
September 9, 2011
-
REGULATORY Council Recommends Subsidization of Peginterferon Therapy for Chronic Active Hepatitis B
September 9, 2011
-
BUSINESS Eisai to Accelerate Clinical Development with Milestone Payments, Signs Agreement on PIII Trials for Lenvatinib
September 8, 2011
-
REGULATORY CSIMC Introduces New Rule for Pricing of High-Priced Drugs; 10 Drugs to Be Reimbursed on Piecework under DPC
September 8, 2011
-
REGULATORY Some CSIMC Members Question NHI Pricing of Nexium Priced at Lower Level Than Omepral
September 8, 2011
-
REGULATORY CSIMC Recommends NHI Price Listing for 15 APIs/20 Products
September 7, 2011
-
ACADEMIA ”Seller’s Market” for Pharmacists Expected to Continue Over Next Few Years
September 7, 2011
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…